CHINA SHINEWAY PHAR.HD-10 ADR

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, CHINA SHINEWAY PHAR.HD-10 ADR has already paid €5.45 in dividends. The last payout was in November.

Financials

In the last quarter, CHINA SHINEWAY PHAR.HD-10 ADR had revenue of €150.64m and net profit of €59.84m

(EUR)	June 2026	YoY
Revenue	150.64m	-
Gross profit	105.3m	-
Net profit	59.84m	-
EBITDA	52.45m	-

Fundamentals

Metric	Value
Market capitalization	€29.84m
Number of shares	1.89m
52-week high/low	€19.94 - €15.06
Dividend yield	32.69%
Dividends TTM	€5.45
Beta	0.72
P/E ratio	6.05
PEG ratio	-1.65
P/B ratio	0.58
P/S ratio	1.81

Company profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.